BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Is Iran using cryptocurrencies to circumvent sanctions? - 2Europe: 4 Urban communities for a Paramount Social Experience
- 3Attacks on Iran's Bushehr nuclear plant and on Iraq border crossing
- 4Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- 5Want to make America healthy again? Stop fueling climate change
- Sought-After Extravagance Ocean side Objections for a Lovely Escape
- This Tiny Neon Frog Dwells in the Clouds
- Change Your Home into an Exercise center with These Famous Wellness Gadgets
- 6 US States for Fly Fishing
- Visual communication Programming for Fledglings
- The Electric Bicycle Americans Can Confide in 2024
- Vote in favor of your Number one Kind of Shades
- AfD faction in western Germany ousts councilman for firebrand speech
- The Best Design Bloggers for Style Motivation
